Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
IPO Year:
Exchange: NASDAQ
Website: https://www.alphatau.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2023 | $8.00 | Buy | Citigroup |
| 4/24/2023 | $9.00 | Buy | H.C. Wainwright |
| 4/14/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 4/8/2022 | $19.00 | Overweight | Piper Sandler |
| 4/4/2022 | $21.00 | Buy | Citigroup |
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t
JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under
JERUSALEM, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Peter Melnyk, a member of its board of directors, has resigned from the Company's Board of Directors in order to assume the full-time position of Alpha Tau's Chief Commercial Officer. Mr. Melnyk served most recently as CEO of Fortovia Therapeutics, an oncology supportive care pharmaceutical and medical device company headquartered in Raleigh, North Carolina. Before that, he served as Chief Commercial Officer of Novocure, and led the construction of the global commercial platform and infrastructure
JERUSALEM, June 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS) (NASDAQ:DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Mr. Gary Leibler has resigned from the Company's board of directors and its audit committee, for reasons unrelated to the Company. "I wish to thank Gary for his years of dedicated service to the Company, as a member of the board of directors since the early days of Alpha Tau," commented Alpha Tau CEO Uzi Sofer. "He has added tremendous value ever since his first day with us, and we have benefitted greatly from his expertise and experience." Gary Leibler, who also serves as
JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
SCHEDULE 13D - Alpha Tau Medical Ltd. (0001871321) (Subject)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
424B5 - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
S-8 - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
20-F - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025. Event:H.C. Wainwright 3rd Annual BioConnect Investor ConferenceFormat:Fireside ChatDate:May 20, 2025Time:3:30 – 4:00PM ETLocation:New York, NY Event:Lytham Partners Spring 2025 Investor ConferenceFormat:1x1 MeetingsDate:May 29, 2025Location:Virtual Mr. Levy will be available for 1x1 investor meetings at both conferences. Please reach out to your H.C. Wainwright and Lytham Partners representa
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025. The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int
JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology. "This is very exciting news for patients suffering from glioblastoma, a highly aggressive form of brain cancer with an extremely poor prognosis and survival rate. In this trial, we will introduce a completely novel approach, which is specifically designed to deliver Alpha DaRT sources into brain tumors that a
- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t
JERUSALEM, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present at the following investor conferences in March 2025. Event:Investor Summit EventFormat:PresentationDate:March 11, 2025Time:12:00PM – 12:30PM ETLocation:Virtual Event:Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceFormat:PresentationDate:March 17, 2025Time:3:20PM – 3:50PM ETLocation:Virtual Event:Sidoti Small Cap ConferenceFormat:PresentationDate:March 19, 2025Time:11:30AM – 12:00PM ETLocation:Virtual Mr. Levy wi
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the achievement of Medical Device Single Audit Program (MDSAP) certification for the company's manufacturing facility in Jerusalem, as part of the Company's commitment to quality, safety, and regulatory compliance while accelerating the global expansion of alpha-radiation cancer therapy through the manufacturing of the Alpha DaRT. MDSAP was established by a coalition of international medical device regulatory authorities from Australia, Brazil, Canada, Japan and the U.S., to
JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. The IDE supplement allows the Company to include an add
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of Alpha DaRT® - - Ad-hoc analyses of pancreatic cancer population subgroups suggest meaningful improvement in median overall survival (OS) for patients treated with Alpha DaRT after prior therapy, compared to previously published studies of alternative monotherapies, across all analyzed subgroups – - Investigational Device Exemption (IDE) received from the FDA to conduct a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with metastatic pancreatic cancer - - Approval received from France's Ministry of Health to commence
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled "Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma," submitted by principal investigators involved in the Company's Israeli pancreatic cancer trial, has been accepted to the 2025 ASCO Gastrointestinal Cancers Symposium, to be held January 23 – 25, 2025 in San Francisco, CA. The poster will be presented during "Poster Session B: Cancers of the Pancr
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00
H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $20.00
Piper Sandler initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $19.00
Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $21.00